


# Supporting the treatment of Alzheimer's patients with explainable artificial intelligence




**Esten H. Leonardsen**

Chief Scientific Officer, baba.vision

Post-doc at the Department of  
Psychology, University of Oslo




# Background



Global Burden of Disease Dementia Forecasting Collaborators (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *The Lancet Public Health*.

# Background




Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine*.

## Eisai dials back forecasts for Alzheimer's drug Leqembi



# Background



Villain, N., Planche, V., & Levy, R. (2022). High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. *Revue neurologique*.

Thank you for your attention!

[esten@baba-vision.com](mailto:esten@baba-vision.com)

